We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Hematologic Complications with Age in Shwachman-Diamond Syndrome

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Image: Bone marrow biopsy from a patient with severe Shwachman-Diamond Syndrome, hypocellular marrow; scattered mild dysplastic changes in all cell lines; may have prominent hematogones (Photo courtesy of Dragos C. Luca, MD)
Image: Bone marrow biopsy from a patient with severe Shwachman-Diamond Syndrome, hypocellular marrow; scattered mild dysplastic changes in all cell lines; may have prominent hematogones (Photo courtesy of Dragos C. Luca, MD)
Shwachman-Diamond syndrome (SDS) is a rare, inherited bone marrow failure, characterized by a low number of white blood cells, poor growth due to difficulty absorbing food, exocrine pancreatic dysfunction, and, in some cases, skeletal abnormalities.

Children with SDS have a small but significant chance of developing blood disorders such as myelodysplastic syndrome (MDS) or leukemia. Nearly 5% of children with the condition will develop leukemia, with the risk rising to 25 % by adulthood. In addition, recurring infections, including pneumonia, ear, and skin infections, are common.

A large team of medical scientists led by those at Harvard Medical School (Boston, MA, USA) conducted a cohort study of 153 subjects from 143 families with confirmed biallelic SBDS mutations enrolled on the North American Shwachman Diamond Registry or Bone Marrow Failure Registry. The team collected longitudinal complete blood counts (CBCs). CBCs were included until the time of myelodysplasia (MDS) or leukemia diagnosis or until the time of hematopoietic stem cell transplant (HSCT), when applicable.

Hemoglobin values were excluded during periods of red cell transfusions, platelet values were excluded during platelet transfusions, and absolute neutrophil counts (ANCs) were excluded while on granulocyte colony-stimulating factor (G-CSF). Local bone marrow aspirate and biopsy reports were examined for reported cellularity (from biopsies), fluorescence in situ hybridization, karyotype, and flow cytometry data. Surveillance bone marrows were defined as bone marrow examinations performed in the absence of clinical symptoms.

The investigators reported that 153 individuals (143 families) with biallelic SBDS mutations, including several short case descriptions illustrating the diversity of phenotypes in SDS. Ninety-two were male (60.1%). Median age at last follow-up was 10.4 years (range, 0.3-52.8). The cohort included 39 adults (25.5%) who were >18 years of age at the follow-up. The SBDS c.258 + 2T>C variant was present in all but one patient.

The team evaluated the association between blood counts and age, 2,146 blood counts were analyzed for 119 subjects. Absolute neutrophil counts were positively associated with age. Hemoglobin was also positively associated with age up to 18 years, but the association was negative thereafter. Platelet counts and marrow cellularity were negatively associated with age. Marrow cellularity did not correlate with blood counts. Severe marrow failure necessitating transplant developed in eight subjects at a median age of 1.7 years (range, 0.4-39.5), with 7/8 requiring transplant prior to age 8 years. Twenty-six subjects (17%) developed a myeloid malignancy (16 myelodysplasia and 10 acute myeloid leukemia) at a median age of 12.3 years (range, 0.5-45.0) and 28.4 years (range, 14.4-47.3), respectively.

The authors concluded that their study found that, although marrow cellularity decreased with age, as expected for a genetic bone marrow failure (BMF) condition, blood counts unexpectedly improved with age. Severe BMF was observed in early childhood, whereas myeloid malignancy was observed in later childhood/early adulthood. The study was published on January 11, 2022 in the journal Blood Advances.

Related Links:
Harvard Medical School

Gold Supplier
All-in-One Solution for All Molecular Testing
STARlet-AIOS
New
Electrolyte Analyzer
K-Lite 5 Series
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
Automatic Immunoassay Analyzer
PATHFAST

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.